Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Asciminib is a novel inhibitor of ABL1 and ABL2 gene fusions in ALL but requires the ABL SH3 domain for efficacy

7 Jun 2024

Abstract excerpt

We read with interest the recent publication by van Outersterp et al 1 describing the differential sensitivity of acute lymphoblastic leukemia (ALL) ABL-class gene fusions to adenosine triphosphate (ATP)-competitive tyrosine kinase inhibitors (TKIs).The aforementioned study investigated the efficacy of imatinib, dasatinib, and bosutinib in cell lines harboring ABL1 (n = 7), ABL2 (n = 1), PDGFRB (n = 11), and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Lymphoblastic Leukemia research
Share to Chronic Myeloid Leukemia Treatments
Share to Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38848536
DOI: 10.1182/blood.2024024776

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Asciminib is a novel inhibitor of ABL1 and ABL2 gene fusions in ALL but requires the ABL SH3 domain for efficacyPMID 38848536Read ↗

Absence of ABL1 exon 2-encoded SH3 residues in BCR::ABL1 destabilizes the autoinhibited kinase conformation and confers resistance to asciminibSemantic proximity Read ↗

The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase.Semantic proximity Read ↗

Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.Semantic proximity Read ↗

ABL1-Directed Inhibitors for CML: Efficacy, Resistance and Future Perspectives.Semantic proximity Read ↗

A novel hyperactive <i>BCR::ABL1</i> <sup> <i>e6a3</i> </sup> variant confers resistance to combined asciminib plus ponatinib therapySemantic proximity Read ↗

BCR::ABL1 kinase N-lobe mutants confer moderate to high degrees of resistance to asciminib.Semantic proximity Read ↗

Tyrosine kinase inhibitor response of ABL-class acute lymphoblastic leukemia: the role of kinase type and SH3 domainSemantic proximity Read ↗

The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.Semantic proximity Read ↗

Autophosphorylation of the oncogenic protein TEL-ABL confers resistance to the allosteric ABL inhibitor asciminibSemantic proximity Read ↗

Targeting the BCR::ABL1 Kinase: Advances Beyond Imatinib in Chronic Myeloid Leukemia.Semantic proximity Read ↗

Asciminib: a new therapeutic option in chronic-phase CML with treatment failure.Semantic proximity Read ↗

Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.